SheriLSpuntMDMBA

Pediatric Hematology & Oncology • Palo Alto, CA

Pediatric Sarcoma Oncology

Endowed Professor of Pediatric Cancer Stanford University School of Medicine

Join to view full profile

Dr. Spunt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spunt's full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8953

Fax+1 650-497-8959

Education & Training

University of TennesseeMBA, Business, 2012 - 2012
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1995 - 1998
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1992 - 1995
University of Michigan Medical SchoolClass of 1992
Stanford UniversityBAS, Biological Sciences and Italian, 1981 - 1986

Certifications & Licensure

CA State Medical License 2013 - 2024
TN State Medical License 1998 - 2013
MD State Medical License 1995 - 1999
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Oxaliplatin in Treating Children With Advanced Solid Tumors Start of enrollment: 2000 Apr 01
Completed
Phase 1
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Start of enrollment: 2007 Feb 05
Completed
Phase 3
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Start of enrollment: 2015 Dec 16
Active, not recruiting
Phase 1, Phase 2
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Start of enrollment: 2019 Jun 13
Recruiting
Phase 1, Phase 2
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body Start of enrollment: 2020 Apr 03
Recruiting
Childhood Cancer Survivor Study Start of enrollment: 1995 Jan 05
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

19 citations
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey
Sarcoma. 2020-04-30
76 citations
Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group S...
Aaron R. Weiss, Elizabeth Lyden, James R. Anderson, Douglas S. Hawkins, Sheri L. Spunt
Journal of Clinical Oncology. 2013-09-10
235 citations
Genome-Informed Targeted Therapy for Osteosarcoma
Leanne C. Sayles, Marcus R. Breese, Amanda Koehne, Stanley G. Leung, Alex G. Lee
Cancer Discovery. 2018-09-28

Press Mentions

You Helped Caroline Ring the Golden BellAugust 19th, 2021
Packard Children’s Cancer Patient Receives Honorary Degree from Her CaregiversOctober 16th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member
Children's Oncology Group
Member
American Society of Pediatric Hematology/Oncology
Member
Connective Tissue Oncology Society
Member
International Society of Pediatric Oncology (SIOP)
Member